Home › NDC Lookup › Labelers › Incyte Corporation

Incyte Corporation NDCs and Package Codes

This page lists NDC package records associated with labeler code 50881 (Incyte Corporation) — including active listings, ingredients, drug names, strengths, dosage forms, package sizes, pricing data when available, and links to each individual NDC page.

Key stats

25
Package NDCs
36
Products
36
Active listings
0
Discontinued
5
Ingredients
0
Therapeutic classes
5
Dosage forms
1
With NADAC pricing

Portfolio

Top ingredients
ruxolitinib 22
axatilimab-csfr 8
pemigatinib 3
retifanlimab-dlwr 2
Tafasitamab-cxix 1
By dosage form
TABLET 13
INJECTION 10
TABLET, EXTENDED RELEASE 10
CREAM 2
INJECTION, POWDER, LYOPHILIZED, FO... 1

Browse records — 36 products

Drug / product Billing NDC NADAC / unit Status
JAKAFI ruxolitinib 10 mg/1 TABLET Incyte · NDC 50881-0010-01 · 28 TABLET in 1 BOTTLE, PLASTIC (50881-010-01) 50881-0010-01 — On market View →
JAKAFI ruxolitinib 25 mg/1 TABLET Incyte · NDC 50881-0025-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-025-60) 50881-0025-60 — On market View →
JAKAFI ruxolitinib 15 mg/1 TABLET Incyte · NDC 50881-0015-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-015-60) 50881-0015-60 — On market View →
JAKAFI ruxolitinib 20 mg/1 TABLET Incyte · NDC 50881-0020-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60) 50881-0020-60 — On market View →
JAKAFI ruxolitinib 5 mg/1 TABLET Incyte · NDC 50881-0005-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-005-60) 50881-0005-60 — On market View →
JAKAFI ruxolitinib 5 mg/1 TABLET Incyte · NDC 50881-0005-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-005-60) 50881-0005-60 — On market View →
JAKAFI ruxolitinib 25 mg/1 TABLET Incyte · NDC 50881-0025-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-025-60) 50881-0025-60 — On market View →
JAKAFI ruxolitinib 15 mg/1 TABLET Incyte · NDC 50881-0015-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-015-60) 50881-0015-60 — On market View →
JAKAFI ruxolitinib 10 mg/1 TABLET Incyte · NDC 50881-0010-01 · 28 TABLET in 1 BOTTLE, PLASTIC (50881-010-01) 50881-0010-01 — On market View →
JAKAFI ruxolitinib 20 mg/1 TABLET Incyte · NDC 50881-0020-60 · 60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60) 50881-0020-60 — On market View →
JAKAFI XR ruxolitinib 11 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0011-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-011-08) 50881-0011-08 — On market View →
JAKAFI XR ruxolitinib 55 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0055-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-055-08) 50881-0055-08 — On market View →
JAKAFI XR ruxolitinib 44 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0044-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-044-08) 50881-0044-08 — On market View →
JAKAFI XR ruxolitinib 33 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0033-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-033-08) 50881-0033-08 — On market View →
JAKAFI XR ruxolitinib 22 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0022-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-022-08) 50881-0022-08 — On market View →
JAKAFI XR ruxolitinib 11 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0011-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-011-08) 50881-0011-08 — On market View →
JAKAFI XR ruxolitinib 22 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0022-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-022-08) 50881-0022-08 — On market View →
JAKAFI XR ruxolitinib 55 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0055-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-055-08) 50881-0055-08 — On market View →
JAKAFI XR ruxolitinib 33 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0033-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-033-08) 50881-0033-08 — On market View →
JAKAFI XR ruxolitinib 44 mg/1 TABLET, EXTENDED RELEASE Incyte · NDC 50881-0044-08 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-044-08) 50881-0044-08 — On market View →
MONJUVI Tafasitamab-cxix 200 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Incyte · NDC 50881-0013-03 · J9349 · 1 VIAL in 1 CARTON (50881-013-03) / 5 mL in 1 VIAL 50881-0013-03 — On market View →
NIKTIMVO axatilimab-csfr 50 mg/mL INJECTION Incyte · NDC 50881-0012-10 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-012-10) / 1 mL in 1 VIAL, SINGLE-USE 50881-0012-10 — On market View →
NIKTIMVO axatilimab-csfr 22 mg/.44mL INJECTION Incyte · NDC 50881-0023-11 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-023-11) / .44 mL in 1 VIAL, SINGLE-USE 50881-0023-11 — On market View →
NIKTIMVO axatilimab-csfr 9 mg/.18mL INJECTION Incyte · NDC 50881-0034-12 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-034-12) / .18 mL in 1 VIAL, SINGLE-USE 50881-0034-12 — On market View →
NIKTIMVO axatilimab-csfr 9 mg/.18mL INJECTION Incyte · NDC 50881-0034-12 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-034-12) / .18 mL in 1 VIAL, SINGLE-USE 50881-0034-12 — On market View →
NIKTIMVO axatilimab-csfr 50 mg/mL INJECTION Incyte · NDC 50881-0012-10 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-012-10) / 1 mL in 1 VIAL, SINGLE-USE 50881-0012-10 — On market View →
NIKTIMVO axatilimab-csfr 22 mg/.44mL INJECTION Incyte · NDC 50881-0023-11 · J9038 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-023-11) / .44 mL in 1 VIAL, SINGLE-USE 50881-0023-11 — On market View →
NIKTIMVO axatilimab-csfr 9 mg/.9mL INJECTION Incyte · NDC 50881-0036-17 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-036-17) / .9 mL in 1 VIAL, SINGLE-USE 50881-0036-17 — On market View →
NIKTIMVO axatilimab-csfr 22 mg/2.2mL INJECTION Incyte · NDC 50881-0047-18 · 1 VIAL, SINGLE-USE in 1 CARTON (50881-047-18) / 2.2 mL in 1 VIAL, SINGLE-USE 50881-0047-18 — On market View →
OPZELURA ruxolitinib 15 mg/g CREAM Incyte · NDC 50881-0007-04 · 1 TUBE in 1 CARTON (50881-007-04) / 5 g in 1 TUBE 50881-0007-04 — On market View →
Where does this data come from?
NDC package records, ingredients, strengths and forms come from the openFDA NDC Directory, grouped by the 5-digit labeler code; pricing is CMS NADAC. This is a factual data directory, not a manufacturer marketing page.